Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
Holders of 5% or more of RGEN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Repligen Corp, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 9.30%5.20M shares | – | Apr 24, 20251 filing | Apr 24, 2025 | SEC |
| FMR LLC | 13G | 5.10%2.89M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.00%2.83M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Repligen Corp, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 202610:38 AM ET | Price T Rowe Associates Inc | 13G/A | 3.10%1.75M shares | −5.10 ppfrom 8.20%Below 5% | Jun 30, 2026 | SEC |
| Jul 31, 202610:45 AM ET | Vanguard Capital Management LLC | 13G | 5.00%2.83M shares | New | Jun 30, 2026 | SEC |
| Mar 27, 202611:37 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 202610:26 AM ET | Price T Rowe Associates Inc | 13G/A | 8.20%4.60M shares | +2.10 ppfrom 6.10% | Dec 31, 2025 | SEC |
| Feb 13, 20263:58 PM ET | Roy T. Eddleman Living Trustand 2 others | 13G/A | 4.81%2.71M shares | –Below 5% | Dec 31, 2025 | SEC |
| Feb 5, 20261:36 PM ET | FMR LLCand 1 other | 13G | 5.10%2.89M shares | New | Dec 31, 2025 | SEC |
| Sep 8, 20251:35 PM ET | Price T Rowe Associates Inc | 13G/A | 6.10%3.43M shares | −6.60 ppfrom 12.70% | Aug 31, 2025 | SEC |
| Apr 24, 20259:52 AM ET | BlackRock, Inc. | 13G/A | 9.30%5.20M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20259:44 AM ET | Price T Rowe Associates Inc | 13G/A | 12.70%7.14M shares | – | Dec 31, 2024 | SEC |
| Feb 13, 202511:20 AM ET | Eddleman Roy Tand 2 others | 13G/A | 4.84%2.71M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 5, 2021 | Eddleman Roy T | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
1 notice from officers, directors and other affiliates planning to sell Repligen Corp shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 20265:04 PM ET | Loeillot OlivierOfficer · Director | 12.9K | $2.46M | Sep 24, 202610b5-1 | Fidelity Brokerage Services LLC | SEC |